Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects

Tucatinib is a potent tyrosine kinase inhibitor selective for human epidermal growth factor receptor 2 (HER2) approved by the US Food and Drug Administration for the treatment of HER2‐positive metastatic breast cancer and in development for other HER2‐positive solid tumors. Modest, reversible serum...

Descripción completa

Detalles Bibliográficos
Autores principales: Topletz‐Erickson, Ariel R., Lee, Anthony J., Mayor, JoAl G., Rustia, Evelyn L., Abdulrasool, Layth I., Wise, Amanda L., Dailey, Ben, DeChenne, Sharon, Walker, Luke N., Alley, Stephen C., Endres, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Transporters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984390/
https://www.ncbi.nlm.nih.gov/pubmed/32989831
http://dx.doi.org/10.1002/jcph.1750

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984390/
https://www.ncbi.nlm.nih.gov/pubmed/32989831
http://dx.doi.org/10.1002/jcph.1750

Ejemplares similares